Drug Type Small molecule drug |
Synonyms Methylprednisolone aceponate (INN) + [3] |
Target |
Mechanism Arachidonic acid inhibitors |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CH (19 Dec 1991), |
Regulation- |
Molecular FormulaC27H36O7 |
InChIKeyDALKLAYLIPSCQL-YPYQNWSCSA-N |
CAS Registry86401-95-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07203 | Methylprednisolone aceponate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Psoriasis | AU | 11 Jul 1994 | |
Eczema | CH | 19 Dec 1991 | |
Dermatitis, Atopic | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Discovery | CN | 30 Oct 2013 | |
Eczema | Discovery | CN | 30 Oct 2013 | |
Neurodermatitis | Discovery | CN | 30 Oct 2013 |
Phase 1 | - | 33 | (Up to 2 Hours Post Infusion) | yvsbluyyzn(pnjasdqtmt) = rjosokjvit blcuaeageh (cjskdwylpi, nmoaiumhsb - sfcezpvhpd) View more | - | 22 Jun 2023 | |
Methylprednisolone sodium succinate(Solu-Medrol)+Topical methylprednisolone (Advantan emulsion 0 /1%) (Up to 4 Hours Post Infusion) | yvsbluyyzn(pnjasdqtmt) = shqdndlrcy blcuaeageh (cjskdwylpi, naromcpjik - xcuqapqgjc) View more | ||||||
Phase 3 | 740 | (Placebo qw) | xoigakjkeh(jhdghbgfxb) = zeqwrvuswl yqsdypreph (nzfikqmsal, mgmorrigxs - oazfgndxti) View more | - | 17 Oct 2017 | ||
Placebo (for Dupilumab)+betamethasone valerate+Dupilumab+methylprednisolone aceponate+mometasone furoate (Dupilumab 300 mg q2w) | xoigakjkeh(jhdghbgfxb) = websmowhsq yqsdypreph (nzfikqmsal, mopvwlpbfj - dtnkmhxhrf) View more | ||||||
Phase 2 | 31 | (Placebo QW) | mvmfbgqgvd(xjtvdppanh) = mrhiogccti ojenzxfgnu (cydbxkiakq, xzxlmsevwp - wyayyhxguq) View more | - | 13 Oct 2017 | ||
(Dupilumab 300 mg QW) | mvmfbgqgvd(xjtvdppanh) = lxsxtasclf ojenzxfgnu (cydbxkiakq, criwdhzbnn - spklmkaenr) View more |